Page 31 - Read Online
P. 31

Sukowati et al. Hepatoma Res 2019;5:2  I  http://dx.doi.org/10.20517/2394-5079.2018.106                                         Page 7 of 9

               - #IG19862 to Tell G) and Reyes PAC by Philippine Council for Health Research and Development (PCHRD)
               and the Hepatology Society of the Philippines (HSP).

               Conflicts of interest
               All authors declared that there are no conflicts of interest.

               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2019.


               REFERENCES
               1.     El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
               2.   Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.
                   Hepatology 2008;48:137-45.
               3.   Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
               4.   Ma S, Chan KW, Guan XY. In search of liver cancer stem cells. Stem Cell Rev 2008;4:179-92.
               5.   Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012;21:283-96.
               6.   Dick JE. Stem cell concepts renew cancer research. Blood 2008;112:4793-807.
               7.   Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, et al. Characterization of a side population of cancer cells from human
                   gastrointestinal system. Stem Cells Dayt Ohio 2006;24:506-13.
               8.   Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, et al. Side population purified from hepatocellular carcinoma cells harbors cancer
                   stem cell-like properties. Hepatology 2006;44:240-51.
               9.   Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer
                   stem/progenitor cells. Biochem Biophys Res Commun 2006;351:820-4.
               10.  Ma S, Chan KW, Hu L, Lee TK, Wo JY, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
                   Gastroenterology 2007;132:2542-56.
               11.  Yin S, Li J, Hu C, Chen X, Yao M, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J
                   Cancer 2007;120:1444-50.
               12.  Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, et al. Identification of local and circulating cancer stem cells in human liver cancer.
                   Hepatology 2008;47:919-28.
               13.  Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell
                   2008;13:153-66.
               14.  Yamashita T, Ji J, Budhu A, Forgues M, Yang W, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with
                   stem/progenitor cell features. Gastroenterology 2009;136:1012-24.
               15.  Kimura O, Takahashi T, Ishii N, Inoue Y, Ueno Y, et al. Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell
                   population in hepatocellular carcinoma cell lines. Cancer Sci 2010;101:2145-55.
               16.  Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, et al. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation
                   through STAT3-mediated NANOG regulation. Cell Stem Cell 2011;9:50-63.
               17.  Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin
                   Invest 2010;120:3326-39.
               18.  Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009;49:S13-21.
               19.  Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV
                   infection and hepatocellular carcinoma. Liver Int 2015;35:2311-7.
               20.  Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer
                   Res 1990;50:3400-7.
               21.  Anfuso B, El-Khobar KE, Ie SI, Avellini C, Radillo O, et al. Activation of hepatic stem cells compartment during hepatocarcinogenesis
                   in a HBsAg HBV-transgenic mouse model. Sci Rep 2018;8:13168.
               22.  Liu Z, Dai X, Wang T, Zhang C, Zhang W, et al. Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by
                   promoting appearance and self-renewal of liver cancer stem cells. Cancer Lett 2017;400:149-60.
               23.  Wang C, Yang W, Yan HX, Luo T, Zhang J, et al. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in
                   3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology 2012;55:108-20.
               24.  Kimura O, Kondo Y, Kogure T, Kakazu E, Ninomiya M, et al. Expression of EpCAM increases in the hepatitis B related and the
                   treatment-resistant hepatocellular carcinoma. Biomed Res Int 2014;2014:172913.
               25.  Arzumanyan A, Friedman T, Ng IO, Clayton MM, Lian Z, et al. Does the hepatitis B antigen HBx promote the appearance of liver
   26   27   28   29   30   31   32   33   34   35   36